DRUG QUANTITY MANAGEMENT POLICY - PER RX

POLICY: Cardiology – Verquvo Drug Quantity Management Policy – Per Rx

• Verquvo[™] (vericiguat tablets – Merck)

REVIEW DATE: 03/29/2022

OVERVIEW

Verquvo, a soluble guanylate cyclase (sGC), is indicated is indicated to **reduce the risk of cardiovascular death and heart failure hospitalization** following a hospitalization for heart failure or need for outpatient intravenous diuretics, in adults with symptomatic chronic heart failure and ejection fraction < 45%.

Dosing

The recommended starting dose of Verquvo is 2.5 mg orally once daily (QD) with food.¹ The dose of Verquvo should be doubled approximately every 2 weeks as tolerated up to the target maintenance dose of 10 mg QD. For patients who are unable to swallow whole tablets, they may be crushed and mixed with water immediately prior to administration.

Availability

Verquvo is available as 2.5 mg, 5 mg, and 10 mg tablets.¹ The 2.5 mg and 5 mg tablets are supplied in bottles of 14 or 30 tablets and cartons of 100 tablets (10 blister packs of 10 tablets each). The 10 mg tablets are supplied in 30 and 90 count bottles, as well as cartons of 100 tablets (10 blister packs of 10 tablets each).

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Verquvo. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per Rx
Verquvo™	2.5 mg tablets	30 tablets
(vericiguat tablets)	5 mg tablets	30 tablets
	10 mg tablets	30 tablets

CRITERIA

Verquvo 2.5 mg tablets

1. If the patient's dose is increasing from 2.5 mg to 5 mg once daily, approve a one-time override of 60 tablets.

Cardiology – Verquvo DQM Policy – Per Rx Page 2

Verquvo 5 mg tablets

1. If the patient's dose is increasing from 5 mg to 10 mg once daily, approve a one-time override of 60 tablets.

Verquvo 10 mg tablets

No overrides recommended.

REFERENCES

1. Verquvo® tablets [prescribing information]. Whitehouse Station, NJ: Merck; June 2021.